Saturday , 13 April 2024
Home Health Global Drug Eluting Balloon Market to Surpass US$ 1,163.0 Million by 2030, Says Coherent Market Insights (CMI)
Health

Global Drug Eluting Balloon Market to Surpass US$ 1,163.0 Million by 2030, Says Coherent Market Insights (CMI)

Major players operating in the market are focusing on getting approval for new products and launching new products in the market. For instance, in February 2021, according to the U.S. Food and Drug Administration (FDA) continues to acknowledge a possible mortality risk with paclitaxel-coated balloons and stents intended to treat new or recurring atherosclerotic lesions in the femoropopliteal artery. A study of paclitaxel-coated stents and balloons used to treat peripheral artery disease in the legs found no evidence of harm associated with the devices, appearing to contradict an earlier mortality signal from a meta-analysis that FDA recommended physicians factor into treatment decisions. The U.S. Food and Drug Administration (FDA) still monitoring safety signal with paclitaxel stents in PAD. The researchers noted several limitations to the new study, including a shorter follow-up time of 2.72 years than the meta-analysis, in which the mortality signal was most apparent in the fourth and fifth years. The findings were presented in February 2021, at the American College of Cardiology's virtual meeting and published in JAMA Internal Medicine. The SAFE-PAD researchers said the study is ongoing and will continue the safety evaluation of the devices until the median follow-up of all patients surpasses five years

 

Major players operating in the market are focusing on getting…

Continue reading your article with a FrontPage News Subscription

Already a Subscriber? Sign In  

OR
VIEW SUBSCRIPTION OPTIONS
Support independent journalism by subscribing